awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47743446-5B91F9D7-4AD1-4442-9DB5-5DBE335BD0AD
Q47743446-5B91F9D7-4AD1-4442-9DB5-5DBE335BD0AD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47743446-5B91F9D7-4AD1-4442-9DB5-5DBE335BD0AD
The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.
P2860
Q47743446-5B91F9D7-4AD1-4442-9DB5-5DBE335BD0AD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47743446-5B91F9D7-4AD1-4442-9DB5-5DBE335BD0AD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1e331dec6bffbc11c586c115457fc27f4a35e79f
P2860
Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.